Ed Arce

WestPark Capital | Healthcare

Ed Arce is an analyst from WestPark Capital specializing in the Healthcare sector. They are beginning to establish their track record, with 3 stock ratings so far. Their current stats show a success rate of 75.61% and an average return of 34.16%.

Ed Arce has only issued 3 ratings so far. While the sample size is small, their early calls show a success rate of 75.61% and an average return of 34.16%. Investors may find their initial activity in the Healthcare sector worth watching as they build a track record.

#1076

Out of 4771

3

Total Ratings

+75.61%

Success Rate

+34.16%

Average Return

Recent Ratings Analysis

AKBA

Sep 08, 2026

Target

$4.50

Current

$0.95

Performance

-8.11%

Ed Arce rated AKBA as Buy on Sep 08, 2026, setting a price target of 4.5. The stock has underperformed, dropping 8.11% despite the bullish target of 4.5.

TLPH

Apr 30, 2026

Target

$3.00

Current

$1.24

Performance

36.41%

On Apr 30, 2026, TLPH was given a Buy rating by Ed Arce, with a target price of 3. The stock rallied 36.41% after the rating, narrowing the gap to the target of 3 and validating the bullish stance.

ENTA

Sep 30, 2025

Target

$28.00

Current

$12.70

Performance

6.10%

ENTA received a Buy rating from Ed Arce on Sep 30, 2025, aiming for 28. Momentum has favored the Buy call, with shares climbing from 12.7 to 12.7, rewarding those who trusted the recommendation.

UNCY

Apr 11, 2025

Target

$7.50

Current

$5.31

Performance

-3.03%

On Apr 11, 2025, Ed Arce published a Buy outlook on UNCY, with a target of 7.5. So far, the stock has neither confirmed nor rejected the Buy case, holding within range of 5.31.

ARCT

Apr 10, 2025

Target

$60.00

Current

$13.98

Performance

49.52%

Ed Arce on Apr 10, 2025 assigned ARCT a Buy rating, with a price target of 60. The Buy call aligned well with market performance, producing a gain of 49.52%.

GALT

Apr 02, 2025

Target

—

Current

$3.90

Performance

195.45%

On Apr 02, 2025, Ed Arce reaffirmed GALT with a Neutral rating, targeting null. Market strength beyond 3.9 went further than the conservative outlook suggested.

IVA

Apr 02, 2025

Target

$13.00

Current

$4.14

Performance

33.55%

IVA was rated Buy by Ed Arce on Apr 02, 2025, with a price objective of 13. A bullish response from the market helped close the gap of 8.86 to the target.

ALGS

Mar 31, 2025

Target

$70.00

Current

$5.33

Performance

-35.39%

On Mar 31, 2025, Ed Arce initiated coverage on ALGS with a Buy rating and target of 70. The Buy call has yet to be validated as shares remain 64.67 away from the target.

DRRX

Mar 27, 2025

Target

—

Current

$1.91

Performance

136.97%

Ed Arce issued a Neutral recommendation for DRRX on Mar 27, 2025, price target set at null. A neutral call gave way to stronger-than-expected performance, closing in on null.

ASMB

Mar 24, 2025

Target

—

Current

$30.46

Performance

173.92%

On Mar 24, 2025, ASMB was evaluated by Ed Arce, who gave a Neutral rating and target of null. Investors who stayed in despite the Hold saw upside of 173.92%.

MTVA

Mar 21, 2025

Target

$12.00

Current

$1.75

Performance

12.90%

Ed Arce rated MTVA as Buy on Mar 21, 2025, setting a price target of 12. The call has proven timely, with shares rising 12.90% toward the price target of 12.

ACXP

Mar 19, 2025

Target

$12.00

Current

$1.40

Performance

-83.27%

On Mar 19, 2025, ACXP was given a Buy rating by Ed Arce, with a target price of 12. Despite the Buy call, shares fell from 1.4 to 1.4, challenging the optimistic stance.

PLRX

Mar 18, 2025

Target

—

Current

$1.13

Performance

-32.74%

PLRX received a Neutral rating from Ed Arce on Mar 18, 2025, aiming for null. The Hold stance proved prudent, with the market softening by 32.74%.

SGMT

Mar 13, 2025

Target

$32.00

Current

$11.06

Performance

215.10%

On Mar 13, 2025, Ed Arce published a Buy outlook on SGMT, with a target of 32. Shares gained 215.10%, underscoring the accuracy of the bullish outlook toward 32.

CDTX

Mar 10, 2025

Target

$35.00

Current

$221.38

Performance

872.24%

Ed Arce on Mar 10, 2025 assigned CDTX a Buy rating, with a price target of 35. The Buy call aligned well with market performance, producing a gain of 872.24%.

AKRO

Mar 03, 2025

Target

$75.00

Current

$54.65

Performance

20.00%

On Mar 03, 2025, Ed Arce reaffirmed AKRO with a Buy rating, targeting 75. The recommendation was supported by strong follow-through as the stock rose from 54.65 to 54.65.

ETNB

Feb 28, 2025

Target

$21.00

Current

$14.84

Performance

60.78%

ETNB was rated Buy by Ed Arce on Feb 28, 2025, with a price objective of 21. A bullish response from the market helped close the gap of 6.16 to the target.

MIRM

Feb 28, 2025

Target

$72.00

Current

$100.61

Performance

111.50%

On Feb 28, 2025, Ed Arce initiated coverage on MIRM with a Buy rating and target of 72. The stock’s climb of 111.50% since the call highlights the foresight in the rating.

MDGL

Feb 27, 2025

Target

$405.00

Current

$533.12

Performance

58.79%

Ed Arce issued a Buy recommendation for MDGL on Feb 27, 2025, price target set at 405. Investors following the Buy call captured upside momentum, with shares now at 533.12.

ARDX

Feb 21, 2025

Target

$5.50

Current

$3.62

Performance

-28.46%

On Feb 21, 2025, ARDX was evaluated by Ed Arce, who gave a Neutral rating and target of 5.5. The Hold call avoided chasing into subsequent weakness of 28.46%.

RARE

Feb 18, 2025

Target

$95.00

Current

$14.40

Performance

-66.99%

Ed Arce rated RARE as Buy on Feb 18, 2025, setting a price target of 95. The stock has underperformed, dropping 66.99% despite the bullish target of 95.

GNFT

Feb 07, 2025

Target

$13.00

Current

$8.95

Performance

128.90%

On Feb 07, 2025, GNFT was given a Buy rating by Ed Arce, with a target price of 13. The stock rallied 128.90% after the rating, narrowing the gap to the target of 13 and validating the bullish stance.

ABUS

Jan 21, 2025

Target

$5.00

Current

$5.12

Performance

59.50%

ABUS received a Buy rating from Ed Arce on Jan 21, 2025, aiming for 5. Momentum has favored the Buy call, with shares climbing from 5.12 to 5.12, rewarding those who trusted the recommendation.

TVTX

Jan 15, 2025

Target

$22.00

Current

$67.51

Performance

273.60%

On Jan 15, 2025, Ed Arce published a Buy outlook on TVTX, with a target of 22. Shares gained 273.60%, underscoring the accuracy of the bullish outlook toward 22.

NAMS

Jan 14, 2025

Target

$48.00

Current

$21.86

Performance

-7.65%

Ed Arce on Jan 14, 2025 assigned NAMS a Buy rating, with a price target of 48. The call has struggled to gain traction, with shares losing 7.65%.

TERN

Dec 04, 2024

Target

$7.50

Current

$52.95

Performance

647.88%

On Dec 04, 2024, Ed Arce reaffirmed TERN with a Neutral rating, targeting 7.5. Market strength beyond 52.95 went further than the conservative outlook suggested.

ITRM

Aug 15, 2024

Target

$5.00

Current

$0.03

Performance

-97.54%

ITRM was rated Buy by Ed Arce on Aug 15, 2024, with a price objective of 5. This case shows how bullish projections can fail, with the stock now below 0.03.

Frequency Asked Questions

Who is Ed Arce?

Ed Arce is an analyst from WestPark Capital specializing in the Healthcare sector.

What is Ed Arce's success rate?

Ed Arce currently has a success rate of +75.61%.

How many ratings has Ed Arce issued?

Ed Arce has issued 3 stock ratings so far.

What is the average return of Ed Arce's calls?

Their stock ratings have generated an average return of +34.16%.

What is Ed Arce's ranking?

Ed Arce is ranked #1076 out of 4771 analysts.

What types of ratings does Ed Arce give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Ed Arce?

You can follow Ed Arce by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Ed Arce?

Their latest rating was a Buy on AKBA issued on 2026-09-08.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep